Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
B-Cell Hodgkin Lymphoma Pipeline market research report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.
Key Targets in the B-Cell Hodgkin Lymphoma Pipeline Market
The key targets in the B-Cell Hodgkin Lymphoma Pipeline market are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19. Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Targets
For more target insights, download a free report sample
Types of MoA in the B-Cell Hodgkin Lymphoma Pipeline Market
The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor. Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 has the maximum number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by MoA
For more MoA insights, download a free report sample
Types of RoA in the B-Cell Hodgkin Lymphoma Pipeline Market
The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intralesional, intraperitoneal, and topical. In the B-Cell Hodgkin Lymphoma Pipeline market, intravenous has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the B-Cell Hodgkin Lymphoma Pipeline Market
The key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Molecule Type
For more molecule type insights, download a free report sample
Key Companies in the B-Cell Hodgkin Lymphoma Pipeline Market
The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc. Bristol-Myers Squibb Co has the majority number of pipeline products.
B-Cell Hodgkin Lymphoma Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2, and Cells Expressing B Lymphocyte Antigen CD19 |
Key MoA | Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor |
Key RoA | Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intralesional, Intraperitoneal, and Topical |
Key molecule types | Small Molecule, Monoclonal Antibody, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Antibody, Antisense RNAi Oligonucleotide, Gene Therapy, and Oligonucleotide |
Key companies | Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Affimed GmbH
Alfasigma SpA
Angiocrine Bioscience Inc
Apollomics Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Biohaven Pharmaceutical Holding Company Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chimeric Therapeutics Ltd
CSL Ltd
CStone Pharmaceuticals Co Ltd
Curis Inc
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eutilex Co Ltd
Faron Pharmaceuticals Oy
Genentech USA Inc
Gibson Oncology LLC
Gilead Sciences Inc
Glenmark Pharmaceuticals Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Helocyte Biosciences Inc
HRAIN Biotechnology Co Ltd
Hutchison MediPharma Ltd
Immune Cell Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Incyte Corp
Inhibrx Inc
Innovent Biologics Inc
Intellia Therapeutics Inc
Kymera Therapeutics Inc
LegoChem Biosciences Inc
Luye Pharma Group Ltd
Magenta Therapeutics Inc
Marker Therapeutics Inc
MediSix Therapeutics Pte Ltd
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec BV & Co KG
Mirati Therapeutics Inc
NewBio Therapeutics Inc
Northlake International LLC
OncoTartis Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
PlantForm Corp
Protheragen Inc
Rafael Pharmaceuticals Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
Seagen Inc
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SpecificiT Pharma Inc
Suzhou Everhealth Biomedical Co Ltd
Syndax Pharmaceuticals Inc
Tacitus Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tessa Therapeutics Ltd
Tevogen Bio Inc
Tubulis GmbH
Tyme Inc
Vincerx Pharma Inc
Viracta Therapeutics Inc
Waterstone Hanxbio Pty Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the B-Cell Hodgkin Lymphoma Pipeline market?
In the B-Cell Hodgkin Lymphoma Pipeline market, the key targets are Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Histone Deacetylase 1, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Histone Deacetylase, Histone Deacetylase 2 and Cells Expressing B Lymphocyte Antigen CD19.
-
What are the types of MoA in the B-Cell Hodgkin Lymphoma Pipeline market?
The key mechanisms of action in the B-Cell Hodgkin Lymphoma Pipeline market are Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Histone Deacetylase 1 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Histone Deacetylase 3 Inhibitor, Leukocyte Surface Antigen CD47 Inhibitor, and Hepatitis A Virus Cellular Receptor 2 Inhibitor.
-
What are the types of RoA in the B-Cell Hodgkin Lymphoma Pipeline market?
The types of key RoA in the B-Cell Hodgkin Lymphoma Pipeline market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, Intralesional, Intraperitoneal, and Topical.
-
What are the key molecule types in the B-Cell Hodgkin Lymphoma Pipeline market?
In the B-Cell Hodgkin Lymphoma Pipeline market, the key molecule types are small molecule, monoclonal antibody, gene-modified cell therapy, monoclonal antibody conjugated, cell therapy, fusion protein, antibody, antisense RNAi oligonucleotide, gene therapy, and oligonucleotide.
-
What are the key companies in the B-Cell Hodgkin Lymphoma Pipeline market?
The key companies in the B-Cell Hodgkin Lymphoma Pipeline market are Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Seagen Inc, Gilead Sciences Inc, Hebei Senlang Biotechnology Co Ltd, Incyte Corp, and Pfizer Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.